Horizon
Mar 07, 2019
Biogen buys Nightstar; Pacira acquires Myoscience; Horizon Pharma announces pricing; STAT with Slingshot Insights; Epizyme announces Equity Offering
Biogen to buy Nightstar for USD 800 Million Biogen known for its efforts in treatments of multiple sclerosis and spinal muscular atrophy wound up the deal to buy Nightstar. The deal will let Biogen have access to two experimental gene therapies for blindness-causing diseases helping Biogen’s pipeline. Pacira...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
